Mitral stenosis · Decision guide
Mitral stenosis: balloon treatment or valve surgery?
Balloon treatment, repair and replacement address different valve anatomy. The cause of the narrowing changes the choice.
At a glance
Mitral stenosis narrows the valve opening. Balloon treatment can preserve a suitable rheumatic valve; heavily calcified disease, blood clots or significant accompanying leakage can make that route unsuitable.
Rheumatic and calcific disease differ
Fused leaflet edges can suit balloon commissurotomy; calcific narrowing does not automatically follow that pathway.
Sources: Mitral valve stenosis: diagnosis and treatment · 2020 ACC/AHA valve guideline: mitral stenosis and tricuspid disease
Medicines do not widen the valve
They can relieve congestion or manage rhythm and clot risk while intervention targets the narrowing.
Replacement creates long-term trade-offs
Mechanical valves require lifelong anticoagulation; tissue valves can deteriorate.
Sources: NHS: valve types
Free Bookimed support. Compare options before deciding.
Benefits and trade-offs
Potential advantages
- Balloon commissurotomy can widen suitable fused leaflets without replacing the native valve.
Trade-offs and limits
- Left-atrial clot, more than mild regurgitation and major commissural calcium are important barriers to balloon treatment.
Sources: 2025 ESC/EACTS valvular heart disease guideline: official recommendation slides · Mitral valve stenosis: diagnosis and treatment
Which kind of narrowing is in the report?
| Report wording | Why it matters |
|---|---|
| Rheumatic mitral stenosis | Fusion of leaflet edges can make balloon commissurotomy an option if the valve is otherwise suitable. |
| Calcific stenosis / mitral annular calcification (MAC) | Calcium around the valve and leaflet bases is a different mechanism. The rheumatic balloon pathway does not automatically apply. |
| Stenosis with regurgitation | Both narrowing and leakage must be assessed. A treatment designed for one problem may not solve the other. |
Sources: 2020 ACC/AHA valve guideline: mitral stenosis and tricuspid disease · Mitral valve stenosis: diagnosis and treatment
Compare the treatment paths
| Path | What it offers | What can rule it out or change it |
|---|---|---|
| Monitoring and medicines | Follow valve severity and relieve congestion or manage rhythm and clot risk. | Medicines do not widen the valve. Symptoms, narrowing severity, pulmonary pressure and anatomy determine whether intervention is appropriate. |
| Balloon commissurotomy / PMBC / PMC | A catheter balloon separates fused leaflet edges while keeping the native valve. | A left-atrial clot, more than mild leakage, major commissural calcium or absent fusion can make it unsuitable. |
| Surgical repair or replacement | An option when symptomatic rheumatic stenosis is unsuitable for balloon treatment; can address other surgical problems. | Repair depends on the remaining valve tissue and calcium. Replacement introduces prosthesis-related trade-offs; combined procedures add operative complexity. |
| Selected catheter replacement for extensive MAC | A specialist option for severe symptomatic dysfunction in some heavily calcified valves. | The 2025 European recommendation is limited; expert-centre review is essential. This is not routine balloon treatment. |
Sources: 2025 ESC/EACTS valvular heart disease guideline: official recommendation slides · Mitral valve stenosis: diagnosis and treatment · 2020 ACC/AHA valve guideline: mitral stenosis and tricuspid disease
Anatomical limits of balloon treatment
Echocardiography identifies valve area, leaflet mobility, calcium, associated leakage and any atrial clot. Fused rheumatic leaflets can suit balloon commissurotomy; major commissural calcium, more than mild regurgitation or a clot can make it unsuitable.
Associated coronary or other valve disease may make a combined operation more appropriate. Additional imaging or exercise testing can clarify symptoms that do not match the resting scan.
Sources: 2025 ESC/EACTS valvular heart disease guideline: official recommendation slides · Mitral valve stenosis: diagnosis and treatment
Interpret the whole treatment course
Residual narrowing, new or remaining leakage and later repeat intervention are different outcomes. Immediate valve opening does not establish long-term durability.
Mechanical replacement requires lifelong anticoagulation; tissue replacement can deteriorate. Rhythm care, follow-up imaging and, in rheumatic disease, prevention of recurrent rheumatic fever can remain part of long-term treatment.
Sources: Mitral valve stenosis: diagnosis and treatment · 2020 ACC/AHA valve guideline: mitral stenosis and tricuspid disease
Specialists for this treatment pathway
Explore each specialist’s clinical focus, current programme and the studies relevant to this treatment. The listed roles include cardiac surgeons and, where appropriate, interventional cardiologists.
A dedicated mitral-stenosis operator shortlist is still being researched. The valve-team directory can help you request a review of rheumatic disease, calcification and repair or replacement options; a general valve profile does not establish stenosis-specific procedural experience.
Continue your guide